Tailoring Treatment for Patients With HR+/HER2- Metastatic Breast Cancer:
Examining the Role of Current and Emerging Endocrine Therapies
Podcast 1 (Aithal): Exploring emerging endocrine therapies in HR+/HER2- MBC
Pre-Test

Questions marked with a * are required
100%
Contact Information
In a 65-year-old woman who experiences progression while on an aromatase inhibitor and a CDK4/6 inhibitor as first-line therapy, which of the following mutations would you look for using liquid next-generation sequencing or ctDNA testing?
In a 65-year-old woman who experiences progression while on an aromatase inhibitor and a CDK4/6 inhibitor as first-line therapy, which of the following mutations would you look for using liquid next-generation sequencing or ctDNA testing?
The EMBER-3 and SERENA-6 trials were analyses of _____ and their ability to reduce HR+/HER2- breast cancer disease progression.
The EMBER-3 and SERENA-6 trials were analyses of _____ and their ability to reduce HR+/HER2- breast cancer disease progression.
Powered by QuestionPro